High-detail single-cell mapping of gene activity and DNA methylation in acute myeloid leukemia
High-throughput single-cell joint RNA and DNA methylation mapping of Acute Myeloid Leukemia
This project develops a faster, lower-cost method to read gene activity and DNA methylation in individual leukemia cells to better understand acute myeloid leukemia.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Icahn School of Medicine at Mount Sinai NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project ID | NIH-11290853 on NIH RePORTER |
What this research studies
You would be part of research that creates a lab technique called SHARE-ME-seq to capture RNA, chromatin accessibility, and DNA methylation from thousands of single cells at once. The team will apply this method to blood and bone marrow samples from people with AML and compare molecular patterns to common mutations such as DNMT3A and TET2. By linking gene activity and methylation in specific cell types, researchers aim to identify the cells and epigenetic changes that drive AML. The findings are intended to guide future biomarker tests and potential targets for therapy rather than provide immediate treatment.
Who could benefit from this research
Good fit: Ideal candidates are people with acute myeloid leukemia who can provide blood or bone marrow samples, including newly diagnosed or relapsed patients.
Not a fit: People without AML or those seeking immediate therapeutic benefit should not expect direct clinical benefit from this research-focused work.
Why it matters
Potential benefit: If successful, this could reveal new biomarkers or targets that help guide future AML diagnosis, monitoring, or treatments.
How similar studies have performed: Related single-cell multi-omic approaches have shown promise in research settings, but joint high-throughput mapping of RNA plus DNA methylation in AML is novel and not yet widely established.
Where this research is happening
New York, United States
- Icahn School of Medicine at Mount Sinai — New York, United States (Active)
Researchers
- Principal investigator: Ma, Sai — Icahn School of Medicine at Mount Sinai
- Study coordinator: Ma, Sai
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.